{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:18Z","timestamp":1792787298548,"version":"4.5.0"},"reference-count":48,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Kalivir Immunotherapeutics","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"https:\/\/ror.org\/009yn9w19","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,2]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oncolytic viruses have pledged to combat cancer by causing immunogenic cell death of cancerous cells while priming cancer-specific immune responses. These outcomes have proven elusive in the clinic. Current-generation vectors rarely reach effective concentrations inside tumors when given intravenously, and consequently are limited to intratumoral administration. Even after direct tumor infusion, these therapies frequently fail to overcome local immunosuppression caused by inappropriate activation of transforming growth factor beta (TGF-\u03b2) signaling throughout the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>VET3-TGI is a vaccinia virus that expresses the chemokine receptor C-X-C chemokine receptor 3 (CXCR3) in infected cells within the first hours after infection. Circulating cells infected in situ on intravenous infusion are driven to migrate to tumors that express cognate chemokines, thus delivering the virus to its target. Infected tumor cells subsequently secrete interleukin-12 (IL-12) and a soluble TGF-\u03b2 inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Expression of CXCR3 from vaccinia virus boosted delivery of virus to tumors containing C-X-C motif chemokine 9 and C-X-C motif chemokine 10, which are known to be upregulated in many human cancers. VET3-TGI effectively combated tumor growth when administered intravenously as a single agent in multiple mouse tumor models. In these models, IL-12 provoked inflammation-driven antitumor activity from immune cells. This activity was strengthened by local TGF-\u03b2 blockade, which crippled the ability of tumors to suppress the immune response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>VET3-TGI demonstrates the efficacy of three different transgenes with distinct and complementary activities: CXCR3 for tumor targeting to enable intravenous delivery, a TGF-\u03b2 inhibitor to disrupt immunosuppression, and IL-12 to promote antitumor immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015643","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:11:16Z","timestamp":1789999876000},"page":"e015643","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6988-9272","authenticated-orcid":false,"given":"Ming","family":"Zhang","sequence":"first","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5933-8893","authenticated-orcid":false,"given":"Katy","family":"Barrett","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Carter","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma","family":"Sampath","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Acosta-Barreto","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Audino","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirapach","family":"Moongdee","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bouchard","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Dunstane","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2787-5603","authenticated-orcid":false,"given":"Nick","family":"Matteo","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Biery","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evalien","family":"Duyvesteyn","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cantos","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M","family":"Brothers","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Byrd","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-1664","authenticated-orcid":false,"given":"Ravikumar","family":"Muthuswamy","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8494-9128","authenticated-orcid":false,"given":"Stephen H","family":"Thorne","sequence":"additional","affiliation":[{"name":"Kalivir Immunotherapeutics Inc, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092107101400000_14.9.e015643.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026092107101400000_14.9.e015643.2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq495"},{"key":"2026092107101400000_14.9.e015643.3","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4661"},{"key":"2026092107101400000_14.9.e015643.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"2026092107101400000_14.9.e015643.5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228627","article-title":"Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials","volume":"21","author":"Hwang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026092107101400000_14.9.e015643.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026092107101400000_14.9.e015643.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0956-8"},{"key":"2026092107101400000_14.9.e015643.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"2026092107101400000_14.9.e015643.9","doi-asserted-by":"crossref","DOI":"10.3390\/cells14221825","article-title":"A Comprehensive Review of Modern Cancer Therapies Utilizing Oncolytic Viruses","volume":"14","author":"Su\u0142ek","year":"2025","journal-title":"Cells"},{"key":"2026092107101400000_14.9.e015643.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.02.020."},{"key":"2026092107101400000_14.9.e015643.11","first-page":"394","article-title":"Genome stability of the vaccine strain VAC\u03946","volume":"26","author":"Maksyutov","year":"2022","journal-title":"Vavilovskii Zhurnal Genet Selektsii"},{"key":"2026092107101400000_14.9.e015643.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2008.07.009"},{"key":"2026092107101400000_14.9.e015643.13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32727"},{"key":"2026092107101400000_14.9.e015643.14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700075"},{"key":"2026092107101400000_14.9.e015643.15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021652"},{"key":"2026092107101400000_14.9.e015643.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-020-01165-x","article-title":"CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis","volume":"19","author":"Yang","year":"2020","journal-title":"Mol Cancer"},{"key":"2026092107101400000_14.9.e015643.17","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000165355.26795.27"},{"key":"2026092107101400000_14.9.e015643.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(01)00032-6"},{"key":"2026092107101400000_14.9.e015643.19","doi-asserted-by":"crossref","DOI":"10.1126\/science.270.5238.908.a","article-title":"IL-12 deaths: explanation and a puzzle","volume":"270","author":"Cohen","year":"1995","journal-title":"Science"},{"key":"2026092107101400000_14.9.e015643.20","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-\u03b2 signaling in health, disease, and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026092107101400000_14.9.e015643.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104380","article-title":"The difficulty in translating the preclinical success of combined TGF\u03b2 and immune checkpoint inhibition to clinical trial","volume":"86","author":"Metropulos","year":"2022","journal-title":"EBioMedicine"},{"key":"2026092107101400000_14.9.e015643.22","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700669"},{"key":"2026092107101400000_14.9.e015643.23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030152"},{"key":"2026092107101400000_14.9.e015643.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3954"},{"key":"2026092107101400000_14.9.e015643.25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40398-4","article-title":"Combined PD-L1\/TGF\u03b2 blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors","volume":"14","author":"Castiglioni","year":"2023","journal-title":"Nat Commun"},{"key":"2026092107101400000_14.9.e015643.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01384-y"},{"key":"2026092107101400000_14.9.e015643.27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.768754"},{"key":"2026092107101400000_14.9.e015643.28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx247"},{"key":"2026092107101400000_14.9.e015643.29","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.4049\/jimmunol.148.11.3433","article-title":"Cloning and expression of murine IL-12","volume":"148","author":"Schoenhaut","year":"1992","journal-title":"J Immunol"},{"key":"2026092107101400000_14.9.e015643.30","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"2026092107101400000_14.9.e015643.31","doi-asserted-by":"publisher","DOI":"10.1038\/S41592-023-02014-7"},{"key":"2026092107101400000_14.9.e015643.32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae410"},{"key":"2026092107101400000_14.9.e015643.33","unstructured":"Index of \/projects\/fastqc\/help [internet]. Available: https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/Help [Accessed 15 Jan 2026]."},{"key":"2026092107101400000_14.9.e015643.34","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3317"},{"key":"2026092107101400000_14.9.e015643.35","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656"},{"key":"2026092107101400000_14.9.e015643.36","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026092107101400000_14.9.e015643.37","doi-asserted-by":"crossref","unstructured":"Korotkevich G , Sukhov V , Budin N , et al . Fast gene set enrichment analysis. Bioinformatics [Preprint] 2016. doi:10.1101\/060012","DOI":"10.1101\/060012"},{"key":"2026092107101400000_14.9.e015643.38","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230053","article-title":"An oncolytic virus-delivered TGF\u03b2 inhibitor overcomes the immunosuppressive tumor microenvironment","volume":"220","author":"DePeaux","year":"2023","journal-title":"J Exp Med"},{"key":"2026092107101400000_14.9.e015643.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"},{"key":"2026092107101400000_14.9.e015643.40","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiae205","article-title":"Interferon-gamma induces epithelial reprogramming driving CXCL11-mediated T-cell migration","volume":"117","author":"Cutilli","year":"2025","journal-title":"J Leukoc Biol"},{"key":"2026092107101400000_14.9.e015643.41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jlb.64.3.384","article-title":"Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12","volume":"64","author":"Kanegane","year":"1998","journal-title":"J Leukoc Biol"},{"key":"2026092107101400000_14.9.e015643.42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206223","article-title":"Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"key":"2026092107101400000_14.9.e015643.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62437-6"},{"key":"2026092107101400000_14.9.e015643.44","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1999.00832.x"},{"key":"2026092107101400000_14.9.e015643.45","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101479","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026092107101400000_14.9.e015643.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.09.007"},{"key":"2026092107101400000_14.9.e015643.47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1152035","article-title":"Late-stage MC38 tumours recapitulate features of human colorectal cancer - implications for appropriate timepoint selection in preclinical studies","volume":"14","author":"Shields","year":"2023","journal-title":"Front Immunol"},{"key":"2026092107101400000_14.9.e015643.48","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040320","article-title":"Combined Inhibition of TGF-\u03b2 Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models","volume":"8","author":"Sow","year":"2019","journal-title":"Cells"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:11:21Z","timestamp":1789999881000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015643"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015643","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}